Advanced Basal Cell Carcinoma: How to Navigate Challenging Clinical Scenarios With Systemic Treatment

Access Activity

Overview / Abstract:

Target Audience
This activity is designed to meet the educational needs of National audience of oncologists, dermatologists, dermato-oncologists, and Mohs surgeons.

Program Overview
Basal cell carcinoma (BCC) is a common type of skin cancer that can be challenging to treat in advanced stages. Join Karl Lewis, MD, and Alexsandar Sekulic, MD, PhD, as they discuss the importance of the hedgehog pathway in the pathogenesis of BCC and the role of hedgehog inhibitors in advanced BCC. Evidence related to the safety and efficacy of the approved hedgehog inhibitors sonidegib and vismodegid is discussed, with recommendations for optimizing their use. Case studies are utilized to share the faculty's experience in treating patients wth hedgehog inhibitors, including strategies to manage resistance.

CONTENT AREAS

Pathogenesis
Hedgehog pathway
Systemic treatment: vismodegib
Systemic treatment: sonidegib
Optimizing hedgehog inhibitors
Emerging agents

Learning Objectives
Upon completion of this activity, participants should be better able to:

Explain how the target pathways of systemic treatment for advanced basal cell carcinoma (BCC) align with the current understanding of the pathogenesis of the disease
Evaluate the profiles of and clinical data related to current and emerging systemic treatments to support the optimal care of patients with advanced BCC
Create systemic treatment plans for patients with advanced BCC who are intolerant to hedgehog pathway inhibitors
Identify opportunities to improve the management of patients with advanced BCC whose disease has progressed despite previous treatment with hedgehog pathway inhibitors

Expiration

Feb 17, 2022

Discipline(s)

Physician CME

Format

Online

Credits / Hours

2.0

Accreditation

ACCME

Presenters / Authors / Faculty

Karl D. Lewis, MD
Aleksandar Sekulic, MD, PhD

Sponsors / Supporters / Grant Providers

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Keywords / Search Terms

Relias LLC Relias, Free CME, Basal Cell Carcinoma Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map